Algen Biotechnologies is combining CRISPR and AI to decode the root cause of disease and accelerate new drug development.
In the week that the Nobel Prize winners for 2025 are being announced, it seems fitting that we kick things off with news from a spin-out from the lab of Nobel laureate and gene editing pioneer Jennifer Doudna. Algen Biotechnologies today announced it has entered a multi-target research partnership with AstraZeneca aimed at accelerating drug discovery through the use of advanced CRISPR gene modulation and AI.
The collaboration, valued at up to $555 million in upfront, near-term, and milestone payments, will apply Algen’s platform to identify new therapeutic targets with human translational relevance. It is thought the company’s approach has the potential to accelerate the identification of novel, actionable targets and reshape how complex diseases, including those linked to aging, are understood and treated.
“Truly transformative therapies begin with uncovering the right biological targets, which have strong human translational relevance,” said AstraZeneca’s Chief Data Scientist Dr Jim Weatherall. “Algen’s platform offers a powerful approach to achieving this.”
Algen’s founders Chun-Hao Huang and Christine Du studied at the UC Berkeley lab led by Doudna, who received the Nobel for Chemistry in 2020 for her work on the gene-editing technology CRISPR. The company’s approach combines single-cell CRISPR gene modulation with AI-driven causal inference to map the molecular underpinnings of disease progression in human cell types. By modeling billions of RNA-level changes and linking them to functional outcomes, the platform seeks to distinguish genes that correlate with disease from those that actually cause it.
Ultimately, Algen’s platform aims to improve translational accuracy and reduce the failure rate that often arises when preclinical discoveries fail to replicate in humans. Its emphasis on modeling human cellular systems appears well-suited to age-related disorders, where disease mechanisms unfold gradually and are influenced by intricate molecular feedback loops.
While the AstraZeneca partnership will focus initially on immunology, where chronic inflammatory diseases often arise from complex and poorly understood signaling networks, Algen claims its approach also has significant potential in aging.
“The underlying approach is highly adaptable and could extend to other complex, multifactorial conditions – including those that emerge with aging, such as neurodegeneration,” Du told us. “By capturing billions of dynamic RNA changes and linking them to functional outcomes, we can identify genes that are not just associated with disease, but truly drive it. That’s where we see real potential to impact age-related disorders: uncovering actionable targets that may slow or even reverse disease processes.”
